Evidence map›Paper›PMID 28270590›Full record

ArticlePhysiological reports2017

Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve disease processes in Emilin1-deficient mouse model.

Charu Munjal, Anil G Jegga, Amy M Opoka, Ivan Stoilov, Russell A Norris, Craig J Thomas, J Michael Smith, Robert P Mecham, Giorgio M Bressan, Robert B Hinton

Open access · goldAbstract read
In one paragraph

Article in Physiological reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Biology and Biomechanics of the Heart Valve Extracellular Matrix.Journal of cardiovascular development and disease · 2020
    Review
  8. Article
  9. Article
  10. Effect of Total Flavones from Cuscuta Chinensis on Anti-Abortion via the MAPK Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2018
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Charu MunjalDivisions of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Anil G JeggaBiomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Amy M OpokaDivisions of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Ivan StoilovDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Ohio.
Russell A NorrisDepartment of Cell Biology, Medical University of South Carolina, Charleston, South Carolina.
Craig J ThomasDivision of Pre-Clinical Innovation, National Center for Advancing Translational Sciences National Institutes of Health, Bethesda, Maryland.
J Michael SmithTriHealth Heart Institute, Cardio-Thoracic Surgery, Cincinnati, Ohio.
Robert P MechamDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Ohio bingrbh@icloud.com.
Giorgio M BressanThe Department of Biomedical Sciences, University of Padua, Padua, Italy.
Robert B HintonDivisions of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Cincinnati Children's Hospital Medical Center · USWashington University in St. Louis · USMedical University of South Carolina · USNational Center for Advancing Translational Sciences · USTriHealth · USUniversity of Padua · IT

Funding

ASSEMBLY OF LUNG ELASTINR01HL053325 · NHLBI · WASHINGTON UNIVERSITY · PI MECHAM, ROBERT P. · 1995 to 2019
$3.6M
VESSEL STIFFENING, HYPERTENSION, AND VASCULAR EXTRACELLULAR MATRIXR01HL105314 · NHLBI · WASHINGTON UNIVERSITY · PI MECHAM, ROBERT P., WAGENSEIL, JESSICA · 2010 to 2018
$3.2M
Genetics and Mechanisms of Mitral Valve ProlapseR01HL127692 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MILAN, DAVID J, SLAUGENHAUPT, SUSAN A · 2015 to 2018
$3.0M
NHLBI NIH HHS R01 HL053325NHLBI NIH HHS R01 HL105314NHLBI NIH HHS R01 HL127692
6 · The paper itself

Abstract

Aortic valve disease (AVD) is a common condition with a progressive natural history, and presently, there are no pharmacologic treatment strategies. Elastic fiber fragmentation (EFF) is a hallmark of AVD, and increasing evidence implicates developmental elastic fiber assembly defects. Emilin1 is a glycoprotein necessary for elastic fiber assembly that is present in both developing and mature human and mouse aortic valves. The

Indexed as

AnimalsAntibodiesAortic ValveBicuspid Aortic Valve DiseaseDiphenylamineDisease Models, AnimalDisease ProgressionDoxycyclineHeart Defects, CongenitalHeart Valve DiseasesMAP Kinase Signaling SystemMembrane GlycoproteinsMiceMice, KnockoutPancreatic ElastaseSulfonamidesAntibodiesDiphenylamineDoxycyclineelastin microfibril interface located proteinMembrane GlycoproteinsN-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamidePancreatic ElastaseSulfonamidesVascular Endothelial Growth Factor AAngiogenesiselastaseselastic fibersfibrosisinflammationvalves

Identifiers

PMID28270590
PMCPMC5350168
OpenAlexW2593449804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.